| Browse All

Sagimet Biosciences Inc. (SGMT)

Healthcare | Biotechnology | San Mateo, United States | NasdaqGM
6.47 USD +0.28 (4.523%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 6.47 +0.00 (0.002%) ⇧ (April 17, 2026, 7:51 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:28 p.m. EDT

SGMT is a highly volatile stock with a negative forward PE and earnings, indicating weak fundamentals. The recent price history shows a range-bound movement, with no clear upward trend. The lack of dividend payouts and weak financial metrics suggest it is not a suitable investment for either short-term or long-term strategies. The options market shows no clear consensus on the direction, making it a risky proposition for speculative trading.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.120212
AutoETS0.121471
AutoARIMA0.121472
AutoTheta0.130513

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 58%
H-stat 2.22
Ljung-Box p 0.000
Jarque-Bera p 0.960
Excess Kurtosis -0.18
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.07
Market Cap 210,825,648
Forward P/E -3.39
Beta 3.21
Website https://www.sagimet.com

As of April 11, 2026, 4:28 p.m. EDT: Options activity shows mixed signals. The ATM strikes are heavily positioned with high open interest and implied volatility, indicating potential for short-term price movements. However, the presence of significant OI in out-of-the-money strikes suggests speculation on both upward and downward trends. The overall volatility is moderate, but the lack of a clear directional bias makes it challenging to determine a strong short-term opportunity.


Info Dump

Attribute Value
52 Week Change 1.5899582
Address1 155 Bovet Road
Address2 Suite 303
All Time High 20.71
All Time Low 1.73
Ask 6.63
Ask Size 3
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 346,580
Average Daily Volume3 Month 523,822
Average Volume 523,822
Average Volume10Days 346,580
Beta 3.212
Bid 6.37
Bid Size 3
Book Value 3.425
City San Mateo
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.47
Current Ratio 22.82
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 6.55
Day Low 6.27
Debt To Equity 0.07
Display Name Sagimet Biosciences
Earnings Timestamp 1,773,232,200
Earnings Timestamp End 1,778,157,000
Earnings Timestamp Start 1,778,157,000
Ebitda Margins 0.0
Enterprise Value 97,779,640
Eps Current Year -1.691
Eps Forward -1.907
Eps Trailing Twelve Months -1.58
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 5.3613
Fifty Day Average Change 1.1086998
Fifty Day Average Change Percent 0.20679682
Fifty Two Week Change Percent 158.99582
Fifty Two Week High 11.41
Fifty Two Week High Change -4.94
Fifty Two Week High Change Percent -0.43295357
Fifty Two Week Low 2.29
Fifty Two Week Low Change 4.18
Fifty Two Week Low Change Percent 1.8253275
Fifty Two Week Range 2.29 - 11.41
Financial Currency USD
First Trade Date Milliseconds 1,689,341,400,000
Float Shares 29,976,669
Forward Eps -1.907
Forward P E -3.3927634
Free Cashflow -30,215,624
Full Exchange Name NasdaqGM
Full Time Employees 16
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.06365
Held Percent Institutions 0.45011002
Implied Shares Outstanding 32,585,107
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,023-07-14
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Long Name Sagimet Biosciences Inc.
Market us_market
Market Cap 210,825,648
Market State CLOSED
Max Age 86,400
Message Board Id finmb_34541828
Most Recent Quarter 1,767,139,200
Net Income To Common -51,038,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 211,151,493
Number Of Analyst Opinions 9
Open 6.27
Operating Cashflow -45,650,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 650 561 8600
Post Market Change 0.0001001358
Post Market Change Percent 0.0015476941
Post Market Price 6.4701
Post Market Time 1,776,469,918
Previous Close 6.19
Price Eps Current Year -3.8261383
Price Hint 2
Price To Book 1.8890511
Profit Margins 0.0
Quick Ratio 22.177
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.3
Region US
Regular Market Change 0.28
Regular Market Change Percent 4.52342
Regular Market Day High 6.55
Regular Market Day Low 6.27
Regular Market Day Range 6.27 - 6.55
Regular Market Open 6.27
Regular Market Previous Close 6.19
Regular Market Price 6.47
Regular Market Time 1,776,456,000
Regular Market Volume 618,524
Return On Assets -0.25696
Return On Equity -0.38204
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 32,017,613
Shares Percent Shares Out 0.099
Shares Short 3,225,311
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 3,659,324
Short Name Sagimet Biosciences Inc. - Seri
Short Percent Of Float 0.1084
Short Ratio 8.83
Source Interval 15
State CA
Symbol SGMT
Target High Price 35.0
Target Low Price 8.0
Target Mean Price 25.77778
Target Median Price 27.0
Total Cash 113,124,000
Total Cash Per Share 3.472
Total Debt 78,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.58
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.8966
Two Hundred Day Average Change -0.42659998
Two Hundred Day Average Change Percent -0.061856568
Type Disp Equity
Volume 618,524
Website https://www.sagimet.com
Zip 94,402